ERBB2 and breast carcinoma: These results demonstrated that combination treatment with neratinib plus everolimus or trametinib significantly enhanced apoptosis in HER2+ breast cancer and TNBC cell lines compared to single-agent treatment with neratinib, everolimus, or trametinib.